摘要
目的探讨血清IL-18和IL-10在肝细胞肝癌(HCC)患者中的变化及其意义。方法采用ELISA法检测65例HCC患者(HCC组)血清IL-18和IL-10水平,并与正常对照组比较。分析HCC患者合并肝硬化(LC)与合并慢性乙型肝炎(CHB)间血清IL-18、IL-10水平的差异。结果HCC组血清IL-18、IL-10水平明显均高于正常对照组(P<0.05);HCC合并LC患者血清IL-18水平明显高于合并CHB患者(P<0.05),而两者间血清IL-10无统计学差异(P>0.05)。结论 HCC患者体内以Th2型免疫反应为主,其血清IL-18、IL-10的水平同时升高可以抑制机体的免疫功能。
Objective To explore the changes and significance of serum IL-18 and IL-10 in the patients with hepatocellular carcinoma（HCC）. Methods Serum IL-18 and IL-10 were detected by ELISA in 65 patients with HCC（group A）. The results were compared with those in the healthy controls（group C）. The difference of serum IL-18 and IL-10 expressions between HCC cases with liver cirrhosis and with chronic hepatitis B were compared as well. Results Serum IL-18 and IL-10 expressions were higher in group A than those in group C（P〈0. 05） ,which in group A were higher in HCA3 cases with liver cirrhosis than those with chronic hepatitis B（P〈0. 05）. Serum IL-10 expression of HCC patients with LC was not significantly different from that in those with chronic hepatitis B （P〉0. 05）. Conclusion The dominant Th2 immune response exists in HCC patients. The increases of seerum IL-18 and IL-10 levels may depress the immune function of HCC patients.
出处
《江苏医药》
CAS
CSCD
北大核心
2012年第13期1516-1518,共3页
Jiangsu Medical Journal
基金
国家自然科学青年基金(81000997)
